Trump Explores Federal Marijuana Reclassification Options

President Donald Trump has announced that his administration is contemplating easing federal marijuana restrictions by reclassifying it to a lower-risk category. This potential change could signify a pivotal moment in the long-held federal stance on marijuana in the U.S.

During a recent press conference, Trump revealed that discussions about altering marijuana's current classification under federal law are taking place. When probed about a possible executive order for reclassification, he indicated that his team is actively examining the proposal.

Many supporters advocate for reclassification, suggesting that the current laws hinder scientific research. Trump noted that stringent federal regulations restrict researchers from comprehensively studying marijuana, and a new classification might facilitate expanded medical and scientific investigation.

Currently, marijuana is classified as a Schedule I substance federally, a designation typically reserved for drugs purported to have high abuse potential and no recognized medical applications. Heroin and LSD also fall under this category, subjecting marijuana to the most stringent federal controls.

Despite federal laws, marijuana regulations differ significantly across states. A number of states have legalized medicinal marijuana, while others permit recreational use. Presently, 24 states, along with Washington, D.C., allow for some form of legal recreational marijuana utilization, illustrating the disconnect between state regulations and federal policy.

Reports suggest that President Trump is leaning towards reclassifying marijuana to Schedule III, a category for substances with recognized medical value and lower abuse potential, which includes drugs like ketamine and anabolic steroids.

It's essential to clarify that reclassifying marijuana would not amount to complete legalization or decriminalization federally but would substantially ease existing restrictions. Experts indicate that this could simplify the process of clinical research, as conducting studies on Schedule I drugs requires navigating numerous regulatory approvals.

This modification might significantly influence the legal cannabis market. Businesses engaged in the lawful cultivation and sale of marijuana could see relief from hefty taxes and reduced regulatory challenges if reclassification occurs.

However, it's important to note that President Trump lacks the authority to unilaterally reclassify a drug. Any modification would necessitate formal actions from federal agencies. Reports indicate that Trump is poised to sign an executive order that would instruct these agencies to initiate the reclassification process.

The topic of marijuana reclassification isn't entirely new; the previous administration had also pursued action to modify its federal classification, but the efforts fell through before Trump assumed office in early 2025.

The U.S. continues to navigate a patchwork of marijuana laws, with each state determining its own policies regarding possession, cultivation, and sales. Trump's remarks indicate that federal marijuana policy is on the cusp of aligning more closely with the established regulations in various states.

If pursued, the reclassification of marijuana could stand out as one of the most significant reforms in drug policy over the past few years, carrying profound implications for research, businesses, and federal enforcement actions.